Menu Search
Equities

Bio-Techne Corp

TE1:MUN

Bio-Techne Corp

Actions
  • Price (EUR)67.00
  • Today's Change2.50 / 3.88%
  • Shares traded1.00
  • 1 Year change+15.52%
  • Beta--
Data delayed at least 15 minutes, as of Nov 22 2024 07:02 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Bio-Techne Corp's net income fell -41.07% from 285.26m to 168.11m despite relatively flat revenues. A contributing factor has been an increase in the selling, general and administrative costs as a percentage of sales from 30.83% to 33.77%.
Gross margin65.93%
Net profit margin12.86%
Operating margin16.29%
Return on assets5.49%
Return on equity7.29%
Return on investment5.77%
More ▼

Cash flow in USDView more

In 2024, cash reserves at Bio-Techne Corp fell by 28.78m. However, the company earned 298.98m from its operations for a Cash Flow Margin of 25.80%. In addition the company used 203.03m on investing activities and also paid 122.40m in financing cash flows.
Cash flow per share1.63
Price/Cash flow per share43.09
Book value per share13.46
Tangible book value per share4.22
More ▼

Balance sheet in USDView more

Bio-Techne Corp has a Debt to Total Capital ratio of 12.30%, a lower figure than the previous year's 22.03%.
Current ratio4.56
Quick ratio3.26
Total debt/total equity0.1403
Total debt/total capital0.123
More ▼

Growth rates in USD

SmartText is unavailable
Div yield(5 year avg)0.38%
Div growth rate (5 year)0.00%
Payout ratio (TTM)33.48%
EPS growth(5 years)11.13
EPS (TTM) vs
TTM 1 year ago		-38.30
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.